Nuveen Asset Management LLC cut its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 79.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,592 shares of the life sciences company’s stock after selling 24,843 shares during the period. Nuveen Asset Management LLC’s holdings in Illumina were worth $1,125,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Advocacy Wealth Management Services LLC purchased a new stake in shares of Illumina during the first quarter valued at $102,000. Advisory Services Network LLC purchased a new stake in shares of Illumina during the first quarter valued at $117,000. Gemmer Asset Management LLC increased its stake in shares of Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock valued at $117,000 after buying an additional 37 shares during the last quarter. Patten Group Inc. increased its stake in shares of Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after buying an additional 25 shares during the last quarter. Finally, Probity Advisors Inc. purchased a new stake in shares of Illumina during the first quarter valued at $204,000. 93.81% of the stock is currently owned by institutional investors and hedge funds.

Illumina, Inc. (NASDAQ ILMN) opened at 197.61 on Wednesday. Illumina, Inc. has a 52-week low of $119.37 and a 52-week high of $199.86. The firm has a market cap of $28.85 billion, a price-to-earnings ratio of 39.65 and a beta of 0.83. The stock has a 50 day moving average of $176.74 and a 200-day moving average of $172.43.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The company had revenue of $662 million during the quarter, compared to analyst estimates of $642.38 million. During the same quarter last year, the firm posted $0.86 EPS. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, analysts expect that Illumina, Inc. will post $3.65 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/09/nuveen-asset-management-llc-has-1-13-million-stake-in-illumina-inc-ilmn-updated-updated.html.

Several analysts have recently weighed in on the stock. Barclays PLC reaffirmed an “equal weight” rating and issued a $150.00 target price on shares of Illumina in a report on Wednesday. Vetr raised shares of Illumina from a “hold” rating to a “buy” rating and set a $209.78 target price on the stock in a report on Wednesday. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $195.00 target price on the stock in a report on Thursday, July 27th. BidaskClub raised shares of Illumina from a “sell” rating to a “hold” rating in a report on Monday. Finally, Cowen and Company reaffirmed an “outperform” rating and issued a $200.00 target price on shares of Illumina in a report on Wednesday, August 2nd. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $177.01.

In other Illumina news, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $180.24, for a total transaction of $3,604,800.00. Following the completion of the sale, the director now directly owns 539,176 shares of the company’s stock, valued at $97,181,082.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Charles Dadswell sold 1,609 shares of the company’s stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $197.00, for a total transaction of $316,973.00. Following the sale, the senior vice president now directly owns 9,037 shares of the company’s stock, valued at $1,780,289. The disclosure for this sale can be found here. Insiders have sold 132,339 shares of company stock valued at $23,619,735 over the last ninety days. Insiders own 1.60% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.